Flow Chemistry for Contemporary Isotope Labeling
Isotope-labeled compounds have emerged as important tools in drug discovery and development. The incorporated isotopes, particularly deuterium, in pharmaceuticals, have...
A Track Record of Success
For those who didn’t notice, X-Chem underwent a major rebranding in mid-2021. We rolled out our new website, logo, color...
What a Year! X‑Chem 2021 in Review
The month of December is often a time to take stock and assess the accomplishments of the past year. As...
Going Beyond Hit ID With Machine Learning & Del: The Prediction of Building Block Reactivity
Since X-Chem and Google’s seminal collaboration applying machine learning (ML) to DNA-encoded chemical library (DEL) screening output, ML has taken...
GHO Capital Acquires X‑Chem, the Leading Provider of DNA-Encoded-Library-Mediated Drug Discovery Services
London, UK – Global Healthcare Opportunities, or GHO Capital Partners LLP (GHO), the European specialist investor in healthcare, announces the acquisition of X-Chem, Inc. (X-Chem), the industry-leading provider of DNA-Encoded Library (DEL)-based discovery services, from an affiliate of The Carlyle Group and Hellman & Friedman LLC.
Driving Discovery Through Miniaturized High-Throughput Chemistry
When chemists approach the formation of a new bond, they often choose reaction conditions that they (or their colleagues) are...
Unlocking Chemical Space: The Power of DEL Screening
Most readers will be familiar with the parable of the “drunkard’s search”, in which a drunk person searches for their...
Otsuka and X‑Chem Enter into a Drug Discovery Research and License Collaboration
Otsuka Pharmaceutical Co., Ltd. (Otsuka) and X-Chem, Inc. (X-Chem) announce that they have signed a collaborative research agreement to advance the discovery process for new Otsuka drug compounds.
Consortium of X‑Chem, Harvard T.H. Chan School of Public Health and Other Leading Academic Institutions Wins Research Award from the Department of Defense
X-Chem, Inc., a privately held biotechnology company with a proprietary and innovative platform to generate small molecule therapeutics, today announced the award of a DOD CDMRP research grant entitled “Chemigenomic Drug Discovery for Tuberculosis.” The grant was awarded to a research consortium led by Eric Rubin, M.D., Ph.D., Irene Heinz professor of Immunology and Infectious Diseases at the Harvard T.H. Chan School of Public Health, and includes researchers from the University of Massachusetts, Worcester; the Joan & Sanford I. Weill Medical College of Cornell University; Rutgers, The State University of New Jersey; Texas A&M AgriLife Research; and X-Chem.